已经提出了几种方法用于在总体人群和预定义亚组中进行测试，重点是控制 $FWER$ $\alpha$。

序贯测试（sequential tests）的拒绝区域基于 $(Z-, Z+)$（标准化检验统计量）进行说明。在所有测试中，$FWER$ 为 $\alpha = 0.025$​​ 。箭头（$\Rightarrow$）显示每个方法中执行假设检验的顺序。 $\alpha_1$表示分配给第一次测试的 $\alpha$，$\alpha_{O}$ 表示分配给整个测试的 $\alpha$。

# Parallel Subgroup Specific (Freidlin et. al. 2010)

One approach is to test specific subgroups with Bonferroni correction on $\alpha$ (parallel subgroupspecific design, Freidlin et al. 2010, 2013). This approach when strong belief exists that the positive group will benefit from the treatment more than the negative group.
该方法通过对 $\alpha$ 进行 $Bonferroni$ 校正来检验特定亚组。当人们坚信 $M_{+}$ 亚组会比 $M_{-}$ 亚组从治疗中受益更多时，就会采用这种方法。

![[./fig/Fig 2.1.1.png]]

# Sequential Subgroup Specific (Douilard et. al 2010)

One can also carry out the test in a sequential manner that provides more design efficiency (Douillard et al. 2010) where the positive group is tested at the level of $\alpha$ and, if the test is significant, the negative group is tested also at the level of $\alpha$.
还可以以顺序方式进行测试，以提供更高的设计效率（Douillard et al. 2010），其中 $M_{+}$ 亚组在 $\alpha$ 水平上进行检验，如果检验显著， $M_{-}$ 亚组也在 $\alpha$ 水平上进行测试。

![[./fig/Fig 2.1.2.png]]

# Fallback Procedure (Simon 2008)

Other strategies include testing the treatment effect in the overall patient population followed by testing in the marker positive group. This strategy offers the opportunity for sponsor to claim efficacy in a patient population as large as possible and is effective when treatment is also beneficial for the marker-negative group, although the treatment effect can be much smaller. A well-known example is the fallback procedure (Simon 2008).
（序贯测试的）其他策略包括先检验总体人群的治疗效果，然后在 $M_{+}$ 亚组中进行测试。该策略为（药物开发）赞助者提供了在尽可能大的患者群体中主张疗效的机会，并且当治疗对 $M_{-}$ 亚组也有益时是有效的，尽管治疗效果可能要小得多。

A well-known example is the fallback procedure (Simon 2008):the treatment effect is tested in the overall population at a reduced level of $\alpha_0$ ; if significant, the procedure stops and an overall effect is claimed; otherwise, the treatment effect is tested in the marker-positive group at $\alpha_{+}$ for claiming efficacy in a sub-population, where $\alpha_{0} + \alpha_{+} = \alpha$. 
一个众所周知的例子是Fallback Procedure（Simon 2008）：在总体人群中以降低的 $\alpha_0$ 水平检验治疗效果；如果显著，则停止程序并主张在总体人群有治疗效果；否则，在 $M_{+}$ 亚组中以 $\alpha_{+}$ 测试治疗效果，以主张在该亚组中有效，其中 $\alpha_{0} + \alpha_{+} = \alpha$。

![[./fig/Fig 2.1.4.png]]

# Two-Stage Test (Song and Chi 2007)

Song and Chi (2007) proposed an approach that takes into account the correlations between the test statistics derived from the overall population and the subgroup. They define a conservative threshold $\alpha_{0}$ and relaxed threshold $\alpha^{*}_{0}$ for the overall p-value, where $\alpha_{0} \lt \alpha \lt \alpha^{*}_0$.  If the overall p-value is less than $\alpha_{0}$ , the treatment effect is considered significant in the overall population and tested in the marker-positive group at level $\alpha$ ; if the overall p-value falls between $\alpha_{0}$ and $\alpha^{*}_{0}$ , the treatment effect in the overall population is borderline and to be tested in the marker-positive group at a more stringent level of $\alpha_{+}$ ($\alpha_{+} \lt \alpha$). If this test is significant, one goes back to test the overall treatment effect at level $\alpha$, where $\alpha_{+}$ is selected conditional on the value of the overall test statistics to control for the $FWER$.
Song 和 Chi (2007) 提出了一种方法，该方法考虑了从总体人群和亚组中得出的检验统计量之间的相关性。他们为总体 p 值定义了保守阈值 $\alpha_{0}$ 和宽松阈值 $\alpha^{*}_{0}$ ，其中 $\alpha_{0} \lt \alpha \lt \alpha^{*}_0$ 。
1. 如果总体 $p$ 值小于 $\alpha_{0}$，则认为治疗效果在总体人群中显着，并在 $M_{+}$ 亚组中的 $\alpha$ 水平进行检验；
2. 如果总体 $p$ 值落在 $\alpha_{0}$ 和 $\alpha^{*}_{0}$ 之间，则总体人群中的治疗效果处于临界状态，需要在 $M_{+}$ 亚组中以更严格的 $\alpha_{+}$ 水平（$\alpha_{+} \lt \alpha$）进行测试。
3. 如果该检验显著，则返回到 $\alpha$ 水平检验总体治疗效果，其中选择 $\alpha_{+}$ 的条件是根据总体检验统计数据的值来控制 $FWER$。
注意：这里提到的总体 $p$ 值、总体检验实质上是指先前的总体人群 $H_{0O}$ 和 $H_{A0}$ 的假设检验。

![[./fig/Fig 2.1.6.png]]

# MaST (Freidlin et. al. 2014)

Freidlin et al. (2014) proposed a marker sequential test (MaST) that involves all three groups (overall, marker positive and negative). It begins with testing the treatment effect in the marker-positive group at a reduced level of $\alpha_{+}$. If treatment effect is significant in the marker-positive group, the marker-negative group is tested at $\alpha$; otherwise, treatment effect is tested in the overall population at $\alpha - \alpha_{+}$. The MaST prioritizes the testing in a subgroup, while the fallback procedure and Song and Chi’s approach prioritize on the overall treatment effect
Freidlin等人（2014）提出了一种标记序贯测试（MaST），涉及所有三组（总体、$M_{+}$ 和 $M_{-}$）。首先测试标志物阳性组在降低的 $\alpha_{+}$ 水平下的治疗效果。如果 $M_{+}$ 亚组治疗效果显著，则 $M_{-}$ 亚组以 $\alpha$ 进行检验；否则，在总体人群中以 $\alpha - \alpha_{+}$ 测试治疗效果。 MaST 优先考虑亚组测试，而 Fallback Procedure 和 Song 与 Chi 的方法（Two-Stage Test）优先考虑整体治疗效果。

![[./fig/Fig 2.1.5.png]]

# Chain Procedure (Millen and Dmitrienko 2011)

A general class of multiple testing procedures called the chain procedure can be applied to subgroup analysis with great flexibility (Dmitrienko and D’Agostino 2013; Millen and Dmitrienko 2011). The procedure is governed by an α allocation rule described by the proportions of $\alpha$ allocated to each hypothesis up-front and an $\alpha$ propagation rule described by the proportions of transferrable $\alpha$ among hypotheses upon rejection.
一类称为链式程序的通用多重检验程序可以非常灵活地应用于亚组分析（Dmitrienko 和 D’Agostino 2013；Millen 和 Dmitrienko 2011）。该过程由 $\alpha$ 分配规则和 $\alpha$ 传播规则组成：
- $\alpha$ 分配规则描述了预先分配给每个假设检验的 $\alpha$ 比例；
- $\alpha$ 传播规则描述了拒绝假设时假设检验之间可转移 $\alpha$ 的比例。

The $\omega_{O}$ and $\omega_{+}$ are the initial weights allocated to the FWER ($\alpha$) for testing the null hypothesis in the overall population and the marker-positive population. The $g_{O+}$ (or $g_{+O}$) is the fractionof the $\alpha$ that can be carried over for testing the null hypothesis in the marker-positive population (or overall population) when the null hypothesis is rejected in the overall population (or marker-positive population).
$\omega_{O}$ 和 $\omega_{+}$ 是分配给 $FWER$ ($\alpha$) 的初始权重，用于检验总体人群和 $M_{+}$ 亚组中的原假设（即 $H_{0O}$ 和 $H_{0+}$）。 $g_{O+}$（或  $g_{+O}$）是当总体人群（或$M_{+}$ 亚组）中的原假设被拒绝（检验显著）时，可结转用于检验$M_{+}$ 亚组（或总体人群）中的原假设的 $\alpha$ 比例。

举例：当总体人群和 $M_{+}$ 亚组的治疗效果同等重要时，分配和传播规则可以指定为 $\omega_{O} = \omega_{+} = 0.5$  和  $g_{O+} = g_{+O} = 1$。那么该链式程序的检验流程如下所示：
首先在具有 $\omega_{O} \alpha$ 的总体人群中检验治疗效果：
- 如果检验显著（即拒绝了原假设），则将分配给总体人群检验的 $\alpha$（即 $\omega_{O} \alpha$）转移到亚组检验，并在 $M_{+}$ 亚组中以 $(\omega_{O}g_{O+} + \omega_{+})\alpha = \alpha$ 的水平检验治疗效果；
- 如果不显著，则在 $M_{+}$ 亚组中以 $\omega_{+}\alpha$ 检验治疗效果。如果显著，则在总体人群中以 $(\omega_{O} + \omega_{+}g_{+O})\alpha = \alpha$ 的水平再次检验治疗效果。
反过来先测试 $M_{+}$ 亚组会得出相同的结论，因为总体人群的检验和 $M_{+}$ 亚组的检验之间 $\alpha$ 的分配是相等的。

![[./fig/Fig 2.1.7.png]]

The Fallback Procedure and the Sequential Subgroup Specific test can be viewed as a simplified version of the chain procedure.
Fallback Procedure和Sequential Subgroup Specific test可以被视为链式过程的简化版本。